The Max Delbrück Center for Molecular Medicine in the Helmholtz Association (MDC) in Berlin, Germany is one of the sixteen research centers of the Helmholtz Association of German Research Centres. It is devoted to biomedical research with the aim of understanding the molecular basis of health and disease and translating findings as quickly as possible into clinical applications. Better prevention, diagnosis and treatment of diseases are the ultimate goals. The MDC's research has a long-time goal: to advance medicine today and in the future. Its broad thematic orientation enables highly networked and collaborative projects providing insights into many different aspects of life and disease. Scientists at the Max Delbrück Center research the biological foundations of human beings in order to understand diseases even better and to prevent illnesses. We want to understand what controls or disturbs the natural balance in individual cells, in an organ or in the whole body. We analyze the human system; the biological basis of life from its most elementary building blocks to cross-organ mechanisms. This knowledge offers the opportunity to effectively prevent diseases, to diagnose them on the basis of the first cell changes, and to stop the progression of diseases with tailored therapies before they can cause major damage to the body. This is what we want to achieve in the research program "Systems Medicine and Cardiovascular Diseases". The overall agenda is divided into three topic areas representing different scales of organization: from "Molecular Processes and Therapies" through "Genes, Cells and Cell based Medicine" to "Integrative Biomedicine". Our work further organizes under cross-cutting areas including microbiomics, data science, imaging, immune- and inflammation-mediated health, single-cell research and translational clinical research.
Role within IMMEDIATE
Within IMMEDIATE, the MDC provides expertise in data science (statistics, machine learning, data management, data integration), epidemiology, confounder analysis, microbiome analysis, immune profiling, proteomics and also access to the German National Cohort (NAKO).